Protalix BioTherapeutics, Inc.

AMEX:PLX

Biotechnology

Healthcare
$3.02 +4.21%

+$0.09 today

Market cap
$254.64M
Beta
0.01
P/E (TTM)
11.0
EPS (TTM)
$0.19
52W Low $1.32High $3.19

Volume 0.96M

Average 0.81M

PLX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Protalix BioTherapeutics, Inc.AMEX: PLX

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $532K fell 1.5% year over year, ahead of the -100.3% change in trailing-twelve-month stock-based compensation. Over 3 fiscal years it compounded at +3.3% a year.

Context

  • Stock-based compensation amounted to 4.4% of revenue in FY2025, down 1.7 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -1.5% holds above the trailing-twelve-month pace of -100.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$532K+134.0% QoQ
Last fiscal yearDec 2025
$2.3M-29.4% YoY
LTMMar 2026
-$8K-100.3% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.5%——
1 year-29.4%——
3-year CAGR+3.3%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
2.3M USD
Year-over-year change
-29.4%
4-year CAGR
-0.8%

Stock-Based Compensation vs competitors

How PLX compares with its peers on the latest reported figures

  • PLX's LTM Mar 2026 stock-based compensation of $8K is the 3rd largest of the 4 companies compared; the peer median is $3.48M.
  • Its year-over-year change of -100.3% is the lowest of 4, against a peer median of -33.4%.
  • Stock-based compensation amounts to 0.0% of revenue for PLX, versus a peer median of 11.1%.
PLX Competitors Peer median
Stock-Based Compensation for PLX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$142.83M -11.3%+5.5%21.3%
PHARPharming Group N.V.LTM Mar 2026$3.48M -33.4%—0.9%
PLXProtalix BioTherapeutics, Inc.LTM Mar 2026$8K -100.3%+3.3%0.0%
PLYXPolaryx Therapeutics, Inc. Common StockFY2025$0 -100.0%——
Peer median (excluding PLX) $3.48M-33.4%+5.5%11.1%

Competitors are the stored peer set for PLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(27.58M)(14.93M)8.31M2.93M(6.6M)
Depreciation & Amortization1.12M1.09M1.19M1.3M1.47M
Deferred Income Tax00(3.09M)236K340K
Stock-Based Compensation2.38M2.09M3.45M3.25M2.3M
Change in Working Capital9.9M(12.02M)(10.54M)811K(10.1M)
Accounts Receivables(1.03M)(1.19M)(428K)2.32M(5.89M)
Inventory(4.87M)1.15M(2.24M)(2.2M)(4.49M)
Accounts Payables00000
Other Working Capital15.81M(11.97M)(7.87M)692K277K
Other Non-Cash Items3.9M(1.23M)(638K)138K608K
Operating Cash Flow(10.29M)(25M)(1.32M)8.67M(11.99M)
Capital Expenditures(1.46M)(628K)(1.15M)(1.28M)(1.64M)
Acquisitions (Net)00000
Purchases of Investments(37.84M)(16M)(20.42M)(15M)(702K)
Sales of Investments57.84M11M5M20.42M0
Other Investing Activities380K593K(142K)83K(26K)
Investing Cash Flow18.92M(5.04M)(16.71M)4.22M(2.37M)
Debt Repayment(34.12M)00(20.42M)0
Common Stock Issued46.2M8.24M23.95M3.63M9.33M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities02K712K00
Financing Cash Flow12.08M8.24M24.67M(16.79M)9.33M
Effect of Forex Changes6K(77K)(114K)25K655K
Net Change in Cash20.72M(21.87M)6.52M(3.87M)(4.38M)
Free Cash Flow(11.74M)(25.63M)(2.47M)7.39M(13.63M)

Protalix BioTherapeutics, Inc.

AMEX:PLX

Intrinsic Alpha fair value

Locked

Current Price

$3.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.